Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.

World neurosurgery - 1 Aug 2023

Wang Haiwei, Wang Xinrui, Xu Liangpu, Zhang Ji

Abstract excerpt

BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) induce extensive transcriptional alterations to promote glioma development. However, IDH1 mutation contributes the better clinical outcomes of glioma. Further understanding the transcriptional and DNA methylation changes mediated by IDH1 mutation will provide new therapeutic targets for glioma. METHODS: Public glioma cohorts were collected and processed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 37271257
DOI: 10.1016/j.wneu.2023.05.109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.PMID 37271257Read ↗

Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

Long non-coding RNA in glioma: novel genetic players in temozolomide resistanceSemantic proximity Read ↗

EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.Semantic proximity Read ↗

Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.Semantic proximity Read ↗

Molecular classification of IDH-mutant glioblastomas based on gene expression profilesSemantic proximity Read ↗

Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.Semantic proximity Read ↗

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancersSemantic proximity Read ↗

A Genome-Wide Profiling of Glioma Patients with an IDH1 Mutation Using the Catalogue of Somatic Mutations in Cancer DatabaseSemantic proximity Read ↗

IGFBP2 expression predicts IDH-mutant glioma patient survival.Semantic proximity Read ↗

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomasSemantic proximity Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.